📊 ICUI Key Takeaways
Is ICUI a Good Investment? Thesis Analysis
ICU Medical's 2787% revenue spike indicates a major acquisition, but the company is severely struggling with profitability and debt service. With 0.5x interest coverage, operating margins of 1.9%, and net profitability near zero on $2.2B revenue, the integration appears challenged and operationally stressed despite positive free cash flow.
Why Buy ICUI? Key Strengths
- Positive operating and free cash flow generation ($179.8M and $91.8M respectively)
- Strong liquidity position with 2.39x current ratio and $308M cash reserves
- Reasonable debt/equity ratio of 0.60x indicating moderate leverage
ICUI Investment Risks to Consider
- Critical: Interest coverage of 0.5x means operating income cannot service debt obligations
- Acquisition integration failure: 2787% revenue growth paired with 0.0% net margin and 1.9% operating margin suggests severe operational distress
- Minimal profitability: $732K net income on $2.2B revenue indicates structural profitability issues, not temporary margin compression
Key Metrics to Watch
- Interest coverage ratio - must improve above 1.0x for financial stability
- Operating margin expansion from 1.9% baseline
- Acquisition synergy realization and integration timeline
ICUI Financial Metrics
💡 AI Analyst Insight
The relatively thin 4.1% FCF margin may limit capital allocation flexibility. Strong liquidity with a 2.39x current ratio provides a solid financial cushion.
ICUI Profitability Ratios
ICUI vs Healthcare Sector
How ICU MEDICAL INC/DE compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ICUI Overvalued or Undervalued?
Based on fundamental analysis, ICU MEDICAL INC/DE shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ICUI Balance Sheet & Liquidity
ICUI 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: ICU MEDICAL INC/DE's revenue has grown significantly by 81% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.23 indicates the company is currently unprofitable.
ICUI Growth Metrics (YoY)
ICUI Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $537.0M | -$3.4M | $-0.14 |
| Q2 2025 | $548.9M | -$15.5M | $0.80 |
| Q1 2025 | $566.7M | -$15.5M | $-0.63 |
| Q3 2024 | $553.3M | $7.2M | $0.30 |
| Q2 2024 | $549.3M | -$9.8M | $-0.41 |
| Q1 2024 | $566.7M | -$9.8M | $-0.41 |
| Q3 2023 | $553.3M | $7.2M | $0.30 |
| Q2 2023 | $549.3M | -$7.5M | $-0.31 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ICUI Capital Allocation
ICUI SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for ICU MEDICAL INC/DE (CIK: 0000883984)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ICUI
What is the AI rating for ICUI?
ICU MEDICAL INC/DE (ICUI) has an AI rating of SELL with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ICUI's key strengths?
Claude: Positive operating and free cash flow generation ($179.8M and $91.8M respectively). Strong liquidity position with 2.39x current ratio and $308M cash reserves.
What are the risks of investing in ICUI?
Claude: Critical: Interest coverage of 0.5x means operating income cannot service debt obligations. Acquisition integration failure: 2787% revenue growth paired with 0.0% net margin and 1.9% operating margin suggests severe operational distress.
What is ICUI's revenue and growth?
ICU MEDICAL INC/DE reported revenue of $2.2B.
Does ICUI pay dividends?
ICU MEDICAL INC/DE does not currently pay dividends.
Where can I find ICUI SEC filings?
Official SEC filings for ICU MEDICAL INC/DE (CIK: 0000883984) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ICUI's EPS?
ICU MEDICAL INC/DE has a diluted EPS of $0.03.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ICUI a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, ICU MEDICAL INC/DE has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ICUI stock overvalued or undervalued?
Valuation metrics for ICUI: ROE of 0.0% (sector avg: 15%), net margin of 0.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ICUI stock in 2026?
Our dual AI analysis gives ICU MEDICAL INC/DE a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ICUI's free cash flow?
ICU MEDICAL INC/DE's operating cash flow is $179.8M, with capital expenditures of $88.0M. FCF margin is 4.1%.
How does ICUI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 0.0% (avg: 12%), ROE 0.0% (avg: 15%), current ratio 2.39 (avg: 2).